mHealth: LabStyle's diabetes management device and mobile app lands E.U. approval
Israeli device maker LabStyle Innovations gains 4% on Wall Street today after announcing plans for "soft launch" of its Dario smartphone-based diabetes management system.
Two-year-old LabStyle Innovations Corp. (OTCQB:DRIO) made the shift from an R&D-stage company to a commercial enterprise with CE Mark approval in the European Union to market its smartphone diabetes management system, the Dario all-inclusive blood glucose monitoring device and mobile data management system.
The mobile app is also a stand-alone program that LabStyle plans to offer to users of other glucose monitors, according to a company statement. The device maker is also hoping to accelerate its FDA 510(k) submission efforts, after which LabStyle will focus on regulatory submissions in Asia and South America.